IRADIMED CORPORATION

NasdaqGM:IRMD Stock Report

Market Cap: US$906.2m

IRADIMED Management

Management criteria checks 4/4

IRADIMED's CEO is Roger Susi, appointed in Jan 2004, has a tenure of 21.75 years. total yearly compensation is $689.58K, comprised of 48.9% salary and 51.1% bonuses, including company stock and options. directly owns 35.95% of the company’s shares, worth $325.78M. The average tenure of the management team and the board of directors is 3.8 years and 6.3 years respectively.

Key information

Roger Susi

Chief executive officer

US$689.6k

Total compensation

CEO salary percentage48.93%
CEO tenure21.8yrs
CEO ownership36.0%
Management average tenure3.8yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up

Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up

IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues

Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues

Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns

Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
User avatar

Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins

Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17
Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13
IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05
At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12
Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

CEO Compensation Analysis

How has Roger Susi's remuneration changed compared to IRADIMED's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

US$21m

Mar 31 2025n/an/a

US$20m

Dec 31 2024US$690kUS$337k

US$19m

Sep 30 2024n/an/a

US$19m

Jun 30 2024n/an/a

US$19m

Mar 31 2024n/an/a

US$18m

Dec 31 2023US$643kUS$308k

US$17m

Sep 30 2023n/an/a

US$16m

Jun 30 2023n/an/a

US$15m

Mar 31 2023n/an/a

US$14m

Dec 31 2022US$586kUS$290k

US$13m

Sep 30 2022n/an/a

US$13m

Jun 30 2022n/an/a

US$12m

Mar 31 2022n/an/a

US$10m

Dec 31 2021US$615kUS$308k

US$9m

Sep 30 2021n/an/a

US$6m

Jun 30 2021n/an/a

US$5m

Mar 31 2021n/an/a

US$987k

Dec 31 2020US$435kUS$290k

US$1m

Sep 30 2020n/an/a

US$4m

Jun 30 2020n/an/a

US$5m

Mar 31 2020n/an/a

US$10m

Dec 31 2019US$488kUS$288k

US$10m

Sep 30 2019n/an/a

US$8m

Jun 30 2019n/an/a

US$8m

Mar 31 2019n/an/a

US$7m

Dec 31 2018US$495kUS$279k

US$6m

Compensation vs Market: Roger's total compensation ($USD689.58K) is below average for companies of similar size in the US market ($USD3.52M).

Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.

CEO

Roger Susi (72 yo)

21.8yrs
Tenure
US$689,580
Compensation

Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Roger Susi
Founder21.8yrsUS$689.58k35.95%
$ 325.8m
John Glenn
CFO & Corporate Secretary3.3yrsUS$1.26m0.10%
$ 936.9k
Jeff Chiprin
Chief Commercial Officerless than a yearUS$483.87kno data
Randy Waddell
Vice President of Worldwide Sales & Marketing4.3yrsUS$597.28k0%
$ 0
Chris Williamson
Executive Vice President of Continuous Improvement & Information Technology3.3yrsno datano data
Matt Garner
Controller5.8yrsno datano data
Lynn Neuhardt
Vice President of Research & Developmentno dataUS$442.20k0%
$ 0
3.8yrs
Average Tenure
63yo
Average Age

Experienced Management: IRMD's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Susi
Founder9.3yrsUS$689.58k35.95%
$ 325.8m
James Hawkins
Director6.3yrsUS$149.95k0.26%
$ 2.4m
Joseph Kiani
Directorless than a yearno datano data
Monty Allen
Independent Director11.8yrsUS$169.95k0.16%
$ 1.4m
Hilda Scharen-Guivel
Independent Director3yrsUS$162.45k0.037%
$ 336.9k
6.3yrs
Average Tenure
69yo
Average Age

Experienced Board: IRMD's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 05:10
End of Day Share Price 2025/10/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IRADIMED CORPORATION is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lawrence SolowCJS Securities, Inc.
Frank TakkinenLake Street Capital Markets, LLC
Jason WittesRoth Capital Partners